推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

mAbs

2023年12月最新中科院分区表数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 MABS-AUSTIN最新评论:这个都没有评论,投的人很少吗? (2022-10-26)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中科院分区:   是否OA期刊:   结果排序:

同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


mAbs期刊基本信息Hello,您是该期刊的第42290位访客

基本信息 登录收藏
期刊名字mAbsmAbs

MABS-AUSTIN
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
7.3
52人评分
我要评分

声誉
8.6

影响力
6.4

速度
6.9

期刊ISSN1942-0862
微信扫码收藏此期刊
E-ISSN1942-0870
2022-2023最新影响因子
(数据来源于搜索引擎)
5.3 点击查看影响因子趋势图
实时影响因子 截止2023年12月27日:4.892
2022-2023自引率11.30%点击查看自引率趋势图
五年影响因子5.3
h-index 65
CiteScore
CiteScoreSJRSNIPCiteScore排名
11.601.7481.351
学科分区排名百分位
大类:Medicine
小类:Immunology and Allergy
Q133 / 211
大类:Medicine
小类:Immunology
Q135 / 217

期刊简介
mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.
期刊官方网站https://www.landesbioscience.com/journals/mabs/
期刊投稿网址https://www.editorialmanager.com/MABS
期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足mAbs的语言要求,还能让mAbs编辑和审稿人得到更好的审稿体验,让稿件最大限度地被mAbs编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢
提交文稿
是否OA开放访问No
通讯方式LANDES BIOSCIENCE, 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, USA, TX, 78701
出版商Landes Bioscience
涉及的研究方向工程技术-仪器仪表
出版国家或地区UNITED STATES
出版语言English
出版周期Bimonthly
出版年份2009
年文章数 86点击查看年文章数趋势图
Gold OA文章占比100.00%
研究类文章占比:
文章 ÷(文章 + 综述)
87.21%
WOS期刊SCI分区
2022-2023年最新版
WOS分区等级:2区

按学科分区JIF分区JIF排名JIF百分位
学科:MEDICINE, RESEARCH & EXPERIMENTAL
类别:SCIE
Q247/136
中科院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中科院SCI期刊分区
2023年12月最新升级版
点击查看中科院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 3区2区4区
MEDICINE, RESEARCH & EXPERIMENTAL
医学:研究与实验
2区4区3区
中科院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 4区2区2区
MEDICINE, RESEARCH & EXPERIMENTAL
医学:研究与实验
4区1区2区
中科院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 3区2区1区
MEDICINE, RESEARCH & EXPERIMENTAL
医学:研究与实验
3区2区2区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
Directory of Open Access Journals (DOAJ)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1942-0862%5BISSN%5D
平均审稿速度网友分享经验:
较慢,6-12周
平均录用比例网友分享经验:
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在mAbs顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 mAbs期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 mAbs中科院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
mAbs上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中科院SCI期刊分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发表论文
  • 中科院SCI期刊分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    MEASUREMENT & CONTROL191.00
    TRANSACTIONS OF THE INSTITUTE OF MEASUREMENT AND CONTROL354.30
    JOURNAL OF DYNAMIC SYSTEMS MEASUREMENT AND CONTROL-TRANSACTIONS OF THE ASME823.90
    LASER PHYSICS LETTERS653.60
    Sensor Review303.70
    Journal of Instrumentation652.20
    tm-Technisches Messen171.70
    AUTOMATION AND REMOTE CONTROL301.60
    中科院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE599642
    BIOMATERIALS512514
    BIOMEDICINE & PHARMACOTHERAPY461597
    Journal of Materials Chemistry B458256
    Frontiers in Pharmacology448029
    Frontiers in Immunology418902
    JOURNAL OF ETHNOPHARMACOLOGY403374
    COLLOIDS AND SURFACES B-BIOINTERFACES402983
    Frontiers in Oncology382325
    Acta Biomaterialia374457
  •  

    mAbs mAbs
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

    Author: Pang, Xinghua; Huang, Zhaoliang; Zhong, Tingting; Zhang, Peng; Wang, Zhongmin Maxwell; Xia, Michelle; Li, Baiyong
    Journal: MABS. 2023; Vol. 15, Issue 1, pp. -. DOI: 10.1080/19420862.2023.2180794
        PubMed      DOI
    2.High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions

    Author: Lourenco, Andre Luiz; Chuo, Shih-Wei; Bohn, Markus F.; Hann, Byron; Khan, Shireen; Yevalekar, Neha; Patel, Nitin; Yang, Teddy; Xu, Lina; Lv, Dandan; Drakas, Robert; Lively, Sarah; Craik, Charles S.
    Journal: MABS. 2023; Vol. 15, Issue 1, pp. -. DOI: 10.1080/19420862.2023.2184197
        PubMed      DOI
    3.Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer

    Author: Guan, Jiawei; Liu, Hongchuan; Chai, Yan; Yu, Jie; Yao, Jian; Wang, Jing; Pan, Zhiwei; Zhang, Jing; Zhou, Yuehua; Liu, Hui; Yao, Sheng; Qi, Jianxun; Feng, Hui; Gao, George. F. F.; Wang, Qihui; Shi, Yi; Tan, Shuguang
    Journal: MABS. 2023; Vol. 15, Issue 1, pp. -. DOI: 10.1080/19420862.2022.2153409
        PubMed      DOI
    4.Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.

    Author: Kuo WY1, Hsu HJ1, Wu CY2, Chen HS1, Chou YC1, Tsou YL1, Peng HP1, Jian JW1,3,4, Yu CM1, Chiu YK1, Chen IC1, Tung CP1, Hsiao M1, Lin CL1, Wang YA5, Wang AH6, Yang AS1.
    Journal: MAbs. 2019 Jan;11(1):153-165. doi: 10.1080/19420862.2018.1541370. Epub 2018 Nov 8.
        PubMed      DOI
    5.Structure, heterogeneity and developability assessment of therapeutic antibodies.

    Author: Xu Y1, Wang D2, Mason B3, Rossomando T3, Li N4, Liu D5, Cheung JK6, Xu W7, Raghava S8, Katiyar A9, Nowak C3, Xiang T10, Dong DD10, Sun J11, Beck A12, Liu H3.
    Journal: MAbs. 2019 Feb/Mar;11(2):239-264. doi: 10.1080/19420862.2018.1553476. Epub 2018 Dec 17.
        PubMed      DOI
    6.De novo generation of specific human IgGs by in vitro immunization using autologous proteins containing immunogenic p-nitrophenylalanine.

    Author: Tong Y1, Fang X1, Tian H1, Zhong S1, Jin L1, Gao X1, Yao W1.
    Journal: MAbs. 2019 Feb/Mar;11(2):401-410. doi: 10.1080/19420862.2018.1537580. Epub 2018 Dec 22.
        PubMed      DOI
    7.Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.

    Author: Xu Y1, Xie L1, Zhang E1, Gao W1, Wang L1, Cao Y1, Xie MH1, Jiang W1, Liu S1.
    Journal: MAbs. 2019 Apr;11(3):606-620. doi: 10.1080/19420862.2019.1578147. Epub 2019 Feb 22.
        PubMed      DOI
    8.Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.

    Author: Liu H1, Guo L2,3, Zhang J1, Zhou Y1, Zhou J1, Yao J1, Wu H1, Yao S1, Chen B1, Chai Y4, Qi J4, Gao GF4, Tan S2,4, Feng H1, Yan J2,3,4.
    Journal: MAbs. 2019 May/Jun;11(4):681-690. doi: 10.1080/19420862.2019.1596513. Epub 2019 Apr 19.
        PubMed      DOI
    9.Important roles of CD32 in promoting suppression of IL-4 induced immune responses by a novel anti-IL-4Rα therapeutic antibody.

    Author: Zhao J1, Jiang L1, Deng L1, Xu W1, Cao Y1, Chen C1, Yang Y1, Wu H1, Huang Y1, Zhu Z1, Huang H1.
    Journal: MAbs. 2019 Apr 5:1-11. doi: 10.1080/19420862.2019.1601985. [Epub ahead of print]
        PubMed      DOI
    10.Multi-Site N-glycan mapping study 1: Capillary electrophoresis - laser induced fluorescence.

    Author: Szekrényes Á, Park SS, Santos M, Lew C, Jones A, Haxo T, Kimzey M, Pourkaveh S, Szabó Z, Sosic Z, Feng P, Váradi C, de l'Escaille F, Falmagne JB, Sejwal P, Niedringhaus T, Michels D, Freckleton G, Hamm M, Manuilov A, Schwartz M, Luo JK, van Dyck J, Leung PK, Olajos M, Gu Y, Gao K, Wang W, Wegstein J, Tep S, Guttman A.
    Journal: MAbs. 2016;8(1):56-64. doi: 10.1080/19420862.2015.1107687. Epub 2015 Oct 14.
        PubMed  
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144642.90
    LANCET700133.20
    NEW ENGLAND JOURNAL OF MEDICINE933134.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION62245.40
    NATURE REVIEWS DRUG DISCOVERY289123.80
    BMJ-British Medical Journal015.30
    BMJ-British Medical Journal015.30
    NATURE REVIEWS IMMUNOLOGY35183.00
    NATURE MEDICINE497107.50
    Nature Reviews Disease Primers4860.90
    同分区等级的其他期刊名称 h-index CiteScore
    Living Reviews in Relativity065.50
    Living Reviews in Relativity7565.50
    JOURNAL OF TRAVEL MEDICINE5119.60
    Military Medical Research030.10
    Advanced Composites and Hybrid Materials016.90
    INTERNATIONAL JOURNAL OF COMPUTER VISION17222.50
    Eurosurveillance9027.70
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE715.70
    Small Structures00.00
    Trends in Chemistry032.10


以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

    同领域作者分享投稿经验:共1条 (包含回复)

我来分享

    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海分公司    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960

    增值电信业务经营许可证:沪B2-20211595

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室

    United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451